JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts.

On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 update expected on May 11, 2026.

Just earlier in the month of April, JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy rating and $11 price target on the shares. The firm has said that AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody discovery platform has advanced 19 molecules into clinical development across both internal and partnered programs spanning multiple therapeutic areas, with its capabilities “best illustrated” through its collaboration with Eli Lilly.

JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based therapies targeting diseases with unmet medical needs.

While we acknowledge the risk and potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABCL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.